Teva Pharmaceutical Industries Limited Share Price TEL AVIV STOCK EXCHANGE
Stocks
TEVA
IL0006290147
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,558.00 ILa | +0.61% |
|
-0.46% | -5.11% |
| 07-09 | Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus | MT |
| 07-09 | Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada | MT |
| Market Cap | 36.19B 0 31.81B 29.62B 27.2B 51.07B 3,471B 51.75B 352B 137B 1,714B 136B 133B 5,923B | P/E 2026 * |
38.4x | P/E 2027 * | 16.9x |
|---|---|---|---|---|---|
| Enterprise Value | 47.35B 0 41.63B 38.75B 35.59B 66.82B 4,541B 67.71B 461B 180B 2,242B 178B 174B 7,750B | EV / Sales 2026 * |
2.85x | EV / Sales 2027 * | 2.59x |
| Free-Float |
88.61% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Limited
| 1 day | +0.78% | ||
| 1 week | -0.46% | ||
| Current month | -2.67% | ||
| 1 month | -3.58% | ||
| 3 months | +2.22% | ||
| 6 months | -3.20% | ||
| Current year | -5.11% |
| 1 week | 9,396 |  | 9,669 |
| 1 month | 9,396 | | 10,730 |
| Current year | 8,860 | | 11,350 |
| 1 year | 5,305 | | 11,350 |
| 3 years | 3,002 | | 11,350 |
| 5 years | 2,383 | | 11,350 |
| 10 years | 2,175 | | 20,860 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 31/12/2022 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 21/12/2019 |
Matthew Shields
COO | Chief Operating Officer | 52 | 02/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 31/12/2008 |
Sol Barer
CHM | Chairman | 78 | 05/02/2017 |
Rosemary Crane
BRD | Director/Board Member | 65 | 31/08/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.60% | -0.46% | - | - | 36.19B | |
| +2.07% | +4.22% | +51.59% | +167.19% | 1,068B | |
| +3.03% | +7.63% | +62.27% | +54.59% | 641B | |
| +3.44% | +2.66% | +39.46% | +74.29% | 454B | |
| +1.78% | +8.99% | +39.60% | +35.04% | 351B | |
| +1.67% | +3.27% | +38.89% | +43.65% | 299B | |
| +1.11% | +2.90% | +19.13% | +16.24% | 266B | |
| +1.61% | +1.96% | -26.76% | -37.47% | 220B | |
| +4.69% | +4.71% | +27.28% | +62.24% | 203B | |
| +3.03% | +2.04% | +17.61% | +72.96% | 162B | |
| Average | +2.38% | +2.76% | +29.90% | +54.30% | 407.04B | |
| Weighted average by Cap. | +2.46% | +2.85% | +39.86% | +80.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.63B 0 14.62B 13.61B 12.5B 23.47B 1,595B 23.78B 162B 63.17B 787B 62.42B 61.08B 2,722B | 17.24B 0 15.15B 14.1B 12.95B 24.32B 1,653B 24.64B 168B 65.48B 816B 64.7B 63.31B 2,821B |
| Net income | 1.31B 0 1.15B 1.07B 982M 1.84B 125B 1.87B 12.71B 4.96B 61.85B 4.9B 4.8B 214B | 2.46B 0 2.17B 2.02B 1.85B 3.48B 236B 3.52B 23.96B 9.36B 117B 9.25B 9.05B 403B |
| Net Debt | 11.16B 0 9.81B 9.13B 8.39B 15.75B 1,070B 15.96B 109B 42.41B 529B 41.9B 41B 1,827B | 8.41B 0 7.39B 6.88B 6.32B 11.86B 806B 12.02B 81.77B 31.93B 398B 31.56B 30.88B 1,376B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/07/26 | ILA 9,558.00 | +0.61% | 484,794 |
| 27/07/26 | ILA 9,500.00 | -0.84% | 1,193,392 |
| 24/07/26 | ILA 9,580.00 | +0.49% | 1,325,339 |
| 22/07/26 | ILA 9,533.00 | -0.88% | 1,061,041 |
| 21/07/26 | ILA 9,618.00 | -0.25% | 1,288,336 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TEVA Stock
- TEVA Stock
Select your edition
All financial news and data tailored to specific country editions
